Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270503 | 0.82 | TP53 (0.45) | MAPTKMT2AALDH1A1KDM4EMEN1 | |
| SCHEMBL9833467 | 0.82 | CDYL2 (0.48) | KMT2AMEN1TP53TGM2 | |
| SCHEMBL5259073 | 0.81 | MAPT (0.45) | MAPTKMT2AHTR7ALDH1A1MEN1 | |
| SCHEMBL5739849 | 0.79 | MAPT (0.44) | MAPTKMT2AHTR7ALDH1A1KDM4E | |
| SCHEMBL7681777 | 0.78 | MAPT (0.58) | MAPTKMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL9830748 | 0.76 | ALDH1A1 (0.34) | MAPTKMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL9834567 | 0.75 | ALDH1A1 (0.35) | MAPTKMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL9672933 | 0.74 | ALPL (0.39) | KMT2AMEN1 | |
| SCHEMBL10545893 | 0.74 | TP53 (0.47) | MAPTKMT2AHTR7MEN1DRD2 | |
| SCHEMBL15075740 | 0.73 | ALDH1A1 (0.43) | MAPTKMT2AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079764-B | Synthesis method of sunitinib intermediate 5-fluoroindol-2-one | 山东汇海医药化工有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-112079764-A | Synthesis method of sunitinib intermediate 5-fluoroindole-2-ketone | 山东汇海医药化工有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-100562319-C | 2-cyanopyrrole and pyrimidine and its pharmaceutical use | NOVARTIS AG (CH) | 2009-11-25 | — | — | CN | disclosed |
| US-7342040-B2 | 5-fluorooxindole-3-carboxylic acid ester | UBE INDUSTRIES, LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| CN-1756553-A | 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20050182123-A1 | 5-Fluorooxindole-3-carboxylic acid ester | UBE INDUSTRIES, LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-6900335-B2 | Process for producing 5-fluorooxindole and for producing intermediates therefor | UBE INDUSTRIES, LTD. (JP) | 2005-05-31 | — | — | US | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20030181731-A1 | Process for producing 5-fluorooxyindole and for producing intermediates therefor | UBE INDUSTRIES., LTD (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1310486-A1 | PROCESS FOR PRODUCING 5-FLUOROOXYINDOLE AND FOR PRODUCING INTERMEDIATE THEREFOR | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | MAPT 2788/4885KMT2A 3122/4885HTR7 3220/4885 |
| US-20050182123-A1 | 5-Fluorooxindole-3-carboxylic acid ester | CYP4F2, AKR7A2, CYP2F1 | MAPT 4521/4885KMT2A 3962/4885HTR7 411/4885 |
| US-20030181731-A1 | Process for producing 5-fluorooxyindole and for producing intermediates therefor | FAR1, CYP4F11, FDPS | MAPT 4135/4885KMT2A 3653/4885HTR7 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.